Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05672108 · ClinicalTrials.gov registry record · Phase 2

Phase II Trial of Lung Chemoemobolization

A Phase 2 study of Sarcoma and Colon Cancer, sponsored by City of Hope Medical Center.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
2
Study locations

NCT05672108 is a Phase 2 study of Sarcoma and Colon Cancer that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 30 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05672108, a Phase 2 study of Sarcoma and Colon Cancer, is actively recruiting participants, sponsored by City of Hope Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor\'s blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.

Interventions

  • PROCEDURE Computed Tomography
  • DRUG Mitomycin
  • PROCEDURE Transarterial Chemoembolization
  • DRUG Ethiodized Oil
  • DEVICE Tris-acryl Gelatin Microspheres

Study Locations (2)

California

  • City of Hope Medical Center - Duarte

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-05-12
Est. Completion 2027-10-28
Phase Phase 2

Sponsor

City of Hope Medical Center

582 total trials

What the Registry Record Tells You About NCT05672108

The ClinicalTrials.gov registry entry for NCT05672108 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (97% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT05672108 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.

Frequently Asked Questions

What is clinical trial NCT05672108 about?

NCT05672108 is a clinical study titled "Phase II Trial of Lung Chemoemobolization". This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then bl...

What is the current status of trial NCT05672108?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-05-12. Estimated completion is 2027-10-28.

What conditions does trial NCT05672108 study?

This clinical trial studies the following conditions: Sarcoma, Colon Cancer, Lung Non-Small Cell Carcinoma, Pleural Neoplasm, Mediastinal Neoplasm.

What interventions are being tested in trial NCT05672108?

The interventions under investigation include: Computed Tomography (PROCEDURE), Mitomycin (DRUG), Transarterial Chemoembolization (PROCEDURE), Ethiodized Oil (DRUG), Tris-acryl Gelatin Microspheres (DEVICE).

Who is sponsoring clinical trial NCT05672108?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05672108 being conducted?

This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.